Subscribe

Biologic Therapy Discontinuation in RA

VBCR - June 2015, Volume 4, No 3 - Rheumatoid Arthritis
Rosemary Frei, MSc

There is an association between discontinuation of biologic therapy in patients with rheumatoid arthritis (RA) and using a lower number of disease-modifying antirheumatic drugs (DMARDs) or not using concomitant methotrexate.

A Canadian team funded by AbbVie Corporation used a database of approximately 22,800 patients with inflammatory disease in Quebec. They focused on 623 adults who had been diagnosed with RA and had been treated with at least one biologic since 2003. Their average age was 53.2 years and 77.1% were women. Furthermore, average disease duration was 7.7 years.

Two hundred and thirty-three patients (37%) had stopped their first biologic treatment after 6 months, while 326 (52%), 405 (65%), and 438 (70%) had done so after 12, 24, and 36 months, respectively. The patients’ average time on their first biologic agent was 1.7 years.

The investigators constructed Cox proportional hazard models that showed working part time was associated with a 57% higher probability of biologic discontinuation over the complete treatment duration compared with working full time, with a hazard ratio (HR) of 1.57. Annual incomes of either $20,000 to $39,999 or $80,000 to $99,999 were both associated with a higher probability of biologic discontinuation than earning less than $20,000, with HRs of 1.35 and 2.16, respectively.

The 2 factors the researchers found to be associated with a lower probability of biologic discontinuation were use of a higher number of DMARDs (HR=0.89) and the concomitant use of methotrexate (HR=0.80).

“AbbVie is interested in the topic of treatment adherence, as we are committed to improving the treatment experience for people living with chronic diseases. We hope that by better understanding the factors associated with lower adherence and treatment discontinuation, we can improve patient outcomes,” according to a statement sent to Value-Based Care in Rheumatology by Scott C. Brun, MD, Vice President, Pharmaceutical Development, AbbVie, Saint-Laurent, Quebec.

Reference

Choquette D, Laliberté M-C, Desjardins O, et al. Biologic discontinuation in rheumatoid arthritis: experience from Canadian clinics. In: Proceedings from the ISPOR 20th International Annual Meeting; May 16-20, 2015; Philadelphia, PA. Abstract PMS60.

Related Items
Working in Cold Environment Increases Risk for RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Treatment with Methotrexate Alone Yields Similar Outcomes to Combination Therapy in Early RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Adalimumab Biosimilar Shown to Be Safe and Effective in Patients with RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Using Preference Phenotypes to Enhance Communication, Facilitate Treatment Decision-Making, and Personalize Care
Leslie Wyatt
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: June 26, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology